资讯
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...
5 天
Stocktwits on MSNGSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their ...GSK plc (GSK) said on Monday that its application for extending the use of its respiratory syncytial virus (RSV) vaccine ...
5 天
GlobalData on MSNGSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patientsGSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...
London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...
5 天
Zacks.com on MSNFDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger AdultsFDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.
GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...
"A regulatory decision by the FDA on this submission is expected in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including in the European Economic ...
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...
Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...
The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.
GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果